BofA Securities Downgrades ResMed (RMD) to Underperform on Valuation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
ResMed (RMD) PT Raised to $270 at Oppenheimer on Philips Recall
June 15, 2021 6:40 AM EDTOppenheimer analyst Suraj Kalia raised the price target on ResMed (NYSE: RMD) to $270.00 (from $240.00) while maintaining an Outperform rating after rival Philips announced a voluntary US recall.
The analyst commented, "Early yesterday (6/14), Philips announced a voluntary US recall (field safety notice RoW) of CPAP and... More
Philips Recall 'Likely Positive' for ResMed (RMD) - Needham & Company
June 14, 2021 11:42 AM EDTNeedham & Company analyst Michael Matson said news that Philips Respironics has issued a formal recall notification for certain sleep and respiratory care products is likely a positive for ResMed (NYSE: RMD).
The analyst commented, "Philips (PHG - Not Rated) Respironics has issued a... More
